GSK plc
General ticker "GLAXF" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $77.9B (TTM average)
GSK plc follows the US Stock Market performance with the rate: 33.5%.
Estimated limits based on current volatility of 0.8%: low 29.31$, high 29.80$
Factors to consider:
- Earnings expected soon, date: nan
- Company pays dividends (semi-annually): last record date 2026-02-20, amount 0.24$ (Y1.63%)
- Total employees count: 90422 as of 2022
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [19.68$, 31.71$]
- 2026-12-31 to 2027-12-31 estimated range: [22.82$, 35.65$]
Financial Metrics affecting the GLAXF estimates:
- Positive: with PPE of 0.4 at the end of fiscal year the price was neutral
- Positive: Operating profit margin, % of 21.95 > 18.52
- Positive: 6.68 < Operating cash flow per share per price, % of 10.20
- Positive: 19.49 < Shareholder equity ratio, % of 26.80 <= 42.60
- Positive: Interest expense per share per price, % of 0.98 <= 3.29
- Positive: Industry operating profit margin (median), % of 26.76 > 9.67
- Positive: Inventory ratio change, % of 0.05 <= 0.80
- Positive: Industry earnings per price (median), % of 6.05 > 4.54
- Positive: Return on assets ratio (scaled to [-100,100]) of 8.55 > 6.12
- Negative: Investing cash flow per share per price, % of -8.17 <= -4.45
Short-term GLAXF quotes
Long-term GLAXF plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | £30,328.00MM | £31,376.00MM | £32,661.71MM |
| Operating Expenses | £23,583.00MM | £27,355.00MM | £25,493.87MM |
| Operating Income | £6,745.00MM | £4,021.00MM | £7,167.84MM |
| Non-Operating Income | £-681.00MM | £-544.00MM | £231.96MM |
| Interest Expense | £775.00MM | £640.00MM | £700.89MM |
| R&D Expense | £6,223.00MM | £6,401.00MM | £7,506.78MM |
| Income(Loss) | £6,064.00MM | £3,477.00MM | £7,399.80MM |
| Taxes | £756.00MM | £526.00MM | £1,111.82MM |
| Profit(Loss)* | £4,928.00MM | £2,575.00MM | £5,715.07MM |
| Stockholders Equity | £13,347.00MM | £13,671.00MM | £16,374.35MM |
| Inventory | £5,498.00MM | £5,669.00MM | £5,923.04MM |
| Assets | £59,005.00MM | £59,463.00MM | £61,108.10MM |
| Operating Cash Flow | £6,768.00MM | £6,554.00MM | £7,301.82MM |
| Capital expenditure | £2,344.00MM | £2,982.00MM | £1,347.78MM |
| Investing Cash Flow | £-1,595.00MM | £-1,229.00MM | £-5,850.05MM |
| Financing Cash Flow | £-5,641.00MM | £-4,726.00MM | £-1,628.74MM |
| Earnings Per Share** | £1.20 | £0.63 | £1.41 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.